Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCR201 in Moderate-to-Advanced Primary Parkinson's Disease Previously Treated With DBS
NCT07896187Phase 1Not yet recruiting
- Sponsor
- Nuwacell Biotechnologies
- Start
- Nov 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Universal iDAP in Parkinson's disease (PD), sponsored by Nuwacell Biotechnologies. Primary endpoints: Incidence of Adverse Events at 12 months and Maximum Tolerated Dose at 12 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
Universal iDAP
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07896187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07896187.